Press "Enter" to skip to content

Aurobindo Pharma completes $300 million deal to acquire 7 oncology products from US-based firm

Aurobindo Pharma completed the acquisition of seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc, a US-based global branded oncology company by Acrotech Biopharma.

Original source:

Also Read:   AstraZeneca's blood cancer drug meets main goal in late-stage trial